BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 23743768)

  • 1. Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline.
    Hennessy EJ; Moore KJ
    J Cardiovasc Pharmacol; 2013 Sep; 62(3):247-54. PubMed ID: 23743768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense technology: an emerging platform for cardiovascular disease therapeutics.
    Lee RG; Crosby J; Baker BF; Graham MJ; Crooke RM
    J Cardiovasc Transl Res; 2013 Dec; 6(6):969-80. PubMed ID: 23856914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small non-coding RNA therapeutics for cardiovascular disease.
    Shah AM; Giacca M
    Eur Heart J; 2022 Nov; 43(43):4548-4561. PubMed ID: 36106499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular RNA interference therapy: the broadening tool and target spectrum.
    Poller W; Tank J; Skurk C; Gast M
    Circ Res; 2013 Aug; 113(5):588-602. PubMed ID: 23948584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides as therapeutics for hyperlipidaemias.
    Crooke RM
    Expert Opin Biol Ther; 2005 Jul; 5(7):907-17. PubMed ID: 16018737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases.
    Bejar N; Tat TT; Kiss DL
    Curr Atheroscler Rep; 2022 May; 24(5):307-321. PubMed ID: 35364795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-coding RNAs: Therapeutic Strategies and Delivery Systems.
    Ling H
    Adv Exp Med Biol; 2016; 937():229-37. PubMed ID: 27573903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of microRNA therapeutics is coming of age.
    van Rooij E; Kauppinen S
    EMBO Mol Med; 2014 Jul; 6(7):851-64. PubMed ID: 24935956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of antisense oligonucleotide and siRNA-based therapeutics.
    Chi X; Gatti P; Papoian T
    Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel cardiovascular therapeutics from small regulatory RNA molecules--an outline of key requirements.
    Poller W; Fechner H
    Curr Pharm Des; 2010; 16(20):2252-68. PubMed ID: 20459390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs.
    Bajan S; Hutvagner G
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.
    Barata P; Sood AK; Hong DS
    Cancer Treat Rev; 2016 Nov; 50():35-47. PubMed ID: 27612280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-based therapeutics for cancer.
    Wang V; Wu W
    BioDrugs; 2009; 23(1):15-23. PubMed ID: 19344188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-targeted therapeutics in cardiovascular disease: the time is now.
    Krychtiuk KA; Rader DJ; Granger CB
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):94-99. PubMed ID: 36138490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA regulation as a therapeutic strategy for cardiovascular disease.
    Montgomery RL; van Rooij E
    Curr Drug Targets; 2010 Aug; 11(8):936-42. PubMed ID: 20415653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases.
    Landmesser U; Poller W; Tsimikas S; Most P; Paneni F; Lüscher TF
    Eur Heart J; 2020 Oct; 41(40):3884-3899. PubMed ID: 32350510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA Therapeutics: the Next Magic Bullet?
    Simonson B; Das S
    Mini Rev Med Chem; 2015; 15(6):467-74. PubMed ID: 25807941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.